Kridin, Khalaf http://orcid.org/0000-0001-9971-9151
Schonmann, Yochai
Onn, Erez
Bitan, Dana Tzur
Weinstein, Orly
Cohen, Arnon D.
Funding for this research was provided by:
Universität zu Lübeck
Article History
Accepted: 12 January 2022
First Online: 16 March 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. No sources of funding were received for the conduct of this study of the preparation of this article.
: ADC served as an advisor, investigator, or speaker for AbbVie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. None of the other authors has any conflicts of interest to declare.
: The study was approved by the institutional review board in accordance with the Declaration of Helsinki (approval code: 0212-17-COM).
: Not applicable.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: KK and ADC had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: KK and ADC. Acquisition, analysis, and interpretation of data: KK, DTB, and TL. Drafting of the manuscript: KK and YS. Critical revision of the manuscript for important intellectual content: KK, ADC, DTB, EO, TL. Statistical analysis: OW and YS. Obtained funding: None. Administrative, technical, or material support: ADC, EO, and OW. Study supervision: KK and ADC.